Stopping Treatment – aHUS Agenda Topic 7
Stopping aHUS treatment when no longer needed is a big decision for patients. Global Action put the patients research agenda question…
aHUS clinical trials are not that easy
To answer some of the questions in the aHUS Patients Research Agenda clinical trials will be needed. Take the issue of…
Monitoring after Eculizumab withdrawal
This article marks the 500th website news “blog” since it went live nearly six years ago. That milestone is marked by…
Withdrawal – need for a consensus
Article No. 457 Yet another article about the outcome of withdrawal of eculizumab treatment has appeared. It is not about a…
Decision Process: Discontinuing aHUS Treatment
Article No 441 18 June 2021 What topics and questions are likely to frame conversations about treating patients who…
aHUS uncertainty is a certainty
Article No. 423 16 March 2021 Update: Seven days after this news blog was published a further report on the ravulizumab…
Atypical HUS in the Netherlands
Atypical HUS in the Netherlands - An aHUS Alliance interview with the Dutch research and clinical teams at Radboudumc, to include the broad importance of their CUREiHUS study and its potential impact for patients and physicians world wide.